Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2014 / Cilt: 23 - Sayı: 1

Tip 4 kardiyorenal sendromda ultrafiltrasyon diüretiklerden daha üstün değildir

Ultrafiltration is not superior than diuretics in type 4 cardiorenal sydrome

Pages
20–25
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: In Type 4 CRS, mortality and hospital admissions were not reduced by UF treatment but cardiac function assessed by EF was significantly improved suggesting this therapy to be beneficial in appropriate patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Cardiorenal syndrome (CRS) describes a dysregulation of the heart and kidneys affecting each other.
📊
Key Findings & Data:MATERIAL and METHODS: Thirty-four Type 4 CRS diagnosed patients were included.
💡
Conclusion & Impact:CONCLUSION: In Type 4 CRS, mortality and hospital admissions were not reduced by UF treatment but cardiac function assessed by EF was significantly improved suggesting this therapy to be beneficial in appropriate patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: Cardiorenal syndrome (CRS) describes a dysregulation of the heart and kidneys affecting each other. Recently hemodialysis treatments were used more frequently. Aim was to analyze the effects of conventional diuretic and UF treatments. MATERIAL and METHODS: Thirty-four Type 4 CRS diagnosed patients were included. Baseline characteristics were recorded. Echocardiography measured at the admission and at the end of the treatment. RESULTS: The mean age 67.4±9.3 (51-93) years and follow-up period were 15.9±11.5 months. The patients were grouped as diuretic group, n=12 and UF group, n=22. At the beginning mitral valve A wave, blood urea nitrogen and creatinine values were higher in the UF group while creatinine values were higher in the UF group compared to diuretic group at the end of the study. Although basal ejection fraction (EF) values were not different, it was higher in the UF group at the end of the study (42.38±12.70 % and 29±3.67 %, p 0.05). CONCLUSION: In Type 4 CRS, mortality and hospital admissions were not reduced by UF treatment but cardiac function assessed by EF was significantly improved suggesting this therapy to be beneficial in appropriate patients.

Özet

AMAÇ: Kardiyorenal sendrom (KRS) birbirlerini etkileyen kalp ve böbrek bozukluklukları olarak tanımlanır. Son zamanlarda bu alanda hemodiyaliz tedavisi tercihi artmıştır. Bu çalışmada amaç geleneksel diüretik ve UF tedavilerinin etkilerini karşılaştırmaktır. GEREÇ ve YÖNTEMLER: Çalışmaya Tip 4 KRS tanısı konulan 34 hasta alındı. Hastaların bazal özellikleri kaydedildi. Başlangıçta ve tedavinin sonunda ekokardiyografik değerlendirme yapıldı. BULGULAR: Hastaların yaş ortalaması 67.4 ± 9.3 (51-93) yıl ve takip süresi 15.9 ± 11.5 ay idi. Hastalar diüretik, n = 12 ve UF grubu, n = 22 olarak sınıflandırıldı. Çalışmanın başında mitral kapak A dalgası, kan üre nitrojeni ve kreatinin değerleri UF grubunda yüksek, çalışmanın sonunda UF grubunda kreatinin değerleri diüretik grubuna göre daha yüksek olarak bulundu. Bazal ejeksiyon fraksiyonu (EF) değerleri her iki grupta farklı olmamasına rağmen UF grubunda çalışmanın sonunda bazale göre artış mevcuttu (42.38 ± 12.70 ve% 29 ± 3.67%, p 0.05). SONUÇ: Tip 4 Kardiyorenal sendromda, UF tedavisi uygulananlarda mortalite ve hastaneye başvurular azalmasa da EF ile değerlendirilen kardiyak fonksiyonlarda anlamlı olarak düzelme olması ile seçilmiş hastalarda bu tedavi etkili olabilir.

🔖

Cite This Article

YILDIRIM, İ., DEMİRTAŞ, O., YAYAR, Ö., CİL, C., KÜÇÜK, E., YAVUZ, N., ACAR, A., KÖSE, Ş., DOĞAN, S. M., SAYIN, M. R., DUMAN, S., YILDIZ, G., HÜR, E., MAĞDEN, K. (2022). Tip 4 kardiyorenal sendromda ultrafiltrasyon diüretiklerden daha üstün değildir. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 23 - Sayı: 1, 20–25. https://ajindex.com/articles/636310

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Heywood JT: The cardiorenal syndrome: Lessons from the ADHERE database and treatment options. Heart Fail Rev 2004;195-201
  2. Forman DE, Butler J, Wang Y, Abraham WT, O’Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young JB, Krumholz HM: Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004; 43: 61-67
  3. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM: Renal impairment and outcomes in heart failure: Systematic review and meta-analysis. J Am Coll Cardiol 2006; 47: 1987-1996
  4. Lassus J, Harjola VP, Sund R, Siirilä-Waris K, Melin J, Peuhkurinen K, Pulkki K, Nieminen MS; FINN-AKVA Study group: Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 2007; 28: 1841-1847 9: van Kimmenade RR, Januzzi JL Jr, Baggish AL, Lainchbury JG, Bayes-Genis A, Richards AM, Pinto YM: Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: Redefining the cardiorenal interaction? J Am Coll Cardiol 2006; 48: 1621-1627
  5. Naruse H, Ishii J, Kawai T, Hattori K, Ishikawa M, Okumura M, Kan S, Nakano T, Matsui S, Nomura M, Hishida H, Ozaki Y: Cystatin C in acute heart failure without advanced renal impairment. Am J Med 2009; 122: 566-573
  6. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527-1539
  7. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Roger VL, Thom T, Wasserthiel- Smoller S, Wong ND, Wylie-Rosett J; American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation 2010; 121(7): e46-e215 Ahmed A, Allman RM, Fonarow GC, Love TE, Zannad F, Dell’italia LJ, White M, Gheorghiade M: Incident heart failure hospitalization and subsequent mortality in chronic heart failure: A propensity- matched study. J Card Fail 2008; 14(3): 211-218
  8. Forster HP, Emanuel E, Grady C: The 2000 revision of the Declaration of Helsinki: A step forward or more confusion? Lancet 2001; 358(9291): 1449-1453 Kidney Dise